Quarterly report [Sections 13 or 15(d)]

Segment Information (Tables)

v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Reconciliation Of Operating Profit Loss From Segments To Consolidated For additional information on the year over year change of segment expenses refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

 

Three Months Ended
March 31,

 

 

 

2026

 

 

2025

 

 

 

(in thousands)

 

Research and development expenses:

 

 

 

 

 

 

Personnel

 

$

12,389

 

 

$

11,365

 

Clinical trials

 

 

10,604

 

 

 

8,511

 

Manufacturing of preclinical and clinical supplies

 

 

10,793

 

 

 

5,032

 

Development services

 

 

2,755

 

 

 

3,567

 

Other research and development costs (1)

 

 

812

 

 

 

543

 

General and administration expenses

 

 

6,943

 

 

 

8,118

 

Interest income

 

 

(1,076

)

 

 

(1,487

)

Interest expense

 

 

636

 

 

 

294

 

Other income, net

 

 

(341

)

 

 

—

 

Net loss

 

$

43,515

 

 

$

35,943

 

(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.